Gülay Güleç CEYLAN, Şükran ERTEN, İsmail DOĞAN, Ebru ATALAR, Kevser GÖK, Serdar Can GÜVEN, Yüksel MARAŞ

The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study

Background/aim: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis. Materials and methods: Forty-six FMF patients receiving anti-interleukin-1 therapy and 36 healthy control patients were compared in terms of laboratory parameters. Also, FMF patients were further divided into two groups; those with amyloidosis and those without it, and these subgroups were compared to each other in terms of clinical and laboratory findings. Results: In comparison between the FMF and healthy control groups, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and red cell distribution width (RDW) level were detected to be higher and hemoglobin level lower in the patient group. Within the FMF patient group, the ESR, CRP, fibrinogen, RDW, and NLR values were significantly higher in the subgroup with amyloidosis in comparison to the subgroup without amyloidosis. Conclusion: Anti-interleukin-1 therapy could not fully suppress the subclinical inflammatory parameters when compared to healthy individuals.

PDF

___

1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43(2): 227–253. doi.org/10.1016/0002- 9343(67)90167-2.
2. Heller H, Sohar E, Pras M. Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathol Microbiol (Basel) 1961; 24: 718–723. doi.org/10.1159/000161188.
3. Kees S, Langevitz P, Zemer D, Padeh S, Pras M et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90 (10): 643–647. doi.org/10.1093/ qjmed/90.10.643.
4. Guzel S, Andican G, Seven A, Aslan M, Bolayirli M et al. Acute phase response and oxidative stress status in familial Mediterranean fever (FMF). Mod Rheumatol 2012; 22 (3): 431–437. doi.org/10.1007/s10165-011-0517-5.
5. Uslu AU, Deveci K, Korkmaz S, Aydin B, Senel S et al. Is neutrophil/lymphocyte ratio associated with subclinical inflammation and amyloidosis in patients with familial Mediterranean fever? Biomed Res Int 2013; 2013: 185317. doi. org/10.1155/2013/185317.
6. Yüksel S, Ayvazyan L, Gasparyan AY. Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J 2010; Feb 23 (4): 51–56. doi.org/10.2174/1874192401004020051.
7. Fonnesu C, Cerquaglia C, Giovinale M, Curigliano V, Verrecchia E et al. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009; 76 (3): 227–233. doi.org/10.1016/j.jbspin.2008.08.004.
8. Manna R, Cerquaglia C, Curigliano V, Fonnesu C, Giovinale M et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci 2009; 13 Suppl 1:51–53.
9. Ahsen A, Ulu MS, Yuksel S, Demir K, Uysal M et al. As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation 2013; 36 (6): 1357–1362. doi.org/10.1007/s10753-013-9675-2.
10. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 2009; 133 (4): 628–632. doi. org/10.1043/1543-2165-133.4.628.
11. Özer S, Yılmaz R, Sönmezgöz E, Karaaslan E, Taşkın S et al. Simple markers for subclinical inflammation in patients with Familial Mediterranean Fever. Med Sci Monit 2015; 21: 298– 303. doi.org/10.12659/MSM.892289.
12. Sakallı H, Kal O. Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever. Clin Rheumatol 2013; 32 (8) :1185–1190. doi.org/10.1007/ s10067-013-2257-8.
13. Uluca Ü, Ece A, Şen V, Karabel D, Yel S et al. Usefulness of mean platelet volume and neutrophil-to-lymphocyte ratio for evaluation of children with Familial Mediterranean fever. Med Sci Monit 2014; 20:1578-82. doi: 10.12659/MSM.892139.
14. Makay B, Türkyilmaz Z, Unsal E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 2009; 28 (8): 975–978. doi.org/10.1007/s10067-009-1148-5.
15. Lachmann HJ. Clinical immunology review series: An approach to the patient with a periodic fever syndrome. Clin Exp Immunol 2011; 165 (3): 301–309. doi.org/10.1111/j.1365- 2249.2011.04438.x.
16. Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci 2020;50 (SI-2): 1591-1610. doi: 10.3906/sag-2008-11.
17. Samli H, Dogru O, Bukulmez A, Yuksel E, Ovali F et al. Relationship of Tel Hashomer criteria and Mediterranean fever gene mutations in a cohort of Turkish familial Mediterranean fever patients. Saudi Med J 2006; 27 (12): 1822–1826.
18. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39 (2): 175- 91. doi: 10.3758/bf03193146.
19. Lachmann HJ, Sengül B, Yavuzşen TU, Booth DR, Booth SE et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45 (6): 746– 750. doi.org/10.1093/rheumatology/kei279.
20. Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. Pediatr Nephrol 2011; 26 (8): 1215–1227. doi.org/10.1007/ s00467-011-1797-x.
21. Pepys MB. Amyloidosis. Annu Rev Med 2006; 57: 223–241. doi.org/10.1146/annurev.med.57.121304.131243.
22. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6 (4): 232–241. doi.org/10.1038/nrrheum.2010.4.
23. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 20 Suppl 2014; 1:S43-58. doi. org/10.2119/molmed.2014.00232.
24. Church LD, McDermott MF. Canakinumab, a fullyhuman mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009; 11 (1): 81–89.
25. Aday AW, Ridker PM. Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. Front Cardiovasc Med 2018; Jun 5 (5): 62. doi.org/10.3389/fcvm.2018.00062.
26. Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; 25 (6): 469–484. doi.org/10.1016/j.smim.2013.10.008.
27. Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm 2019; 2019: 9213074. doi.org/10.1155/2019/9213074.
28. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul fibrinolysis an Int J Haemost Thromb 1996; 7 (2): 157–161.
29. Murat SN, Duran M, Kalay N, Gunebakmaz O, Akpek M et al. Relation between mean platelet volume and severity of atherosclerosis in patients with acute coronary syndromes. Angiology 2013; 64 (2): 131–136. doi. org/10.1177/0003319711436247
30. Yilmaz MB, Cihan G, Guray Y, Guray U, Kisacik HL et al. Role of mean platelet volume in triagging acute coronary syndromes. J Thromb Thrombolysis 2008; 26 (1): 49–54. doi. org/10.1007/s11239-007-0078-9.
31. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17 (1): 47–58. doi. org/10.2174/138161211795049804.
32. Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy. Rheumatol Int 2010; 30 (8): 1125–1129. doi.org/10.1007/s00296-009-1345-1.
33. Yazici S, Yazici M, Erer B, Erer B, Calik Y et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets 2010; 21 (2): 122–125. doi.org/10.3109/09537100903474373.
34. Ozsu S, Abul Y, Gulsoy A, Bulbul Y, Yaman S, et al. Red cell distribution width in patients with obstructive sleep apnea syndrome. Lung 2012; 190 (3): 319–326. doi.org/10.1007/ s00408-012-9376-x.
35. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50 (1): 40–47. doi. org/10.1016/j.jacc.2007.02.067.
36. Patel K V, Ferrucci L, Ershler WB, Longo DL, Guralnik JM. Red blood cell distribution width and the risk of death in middleaged and older adults. Arch Intern Med 2009; 169 (5): 515–523. doi.org/10.1001/archinternmed.2009.11.
37. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008; 54 (2): 335–342. doi.org/10.1373/clinchem.2007.100271
38. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54 (1): 24–38. doi.org/10.1373/ clinchem.2007.097360.
39. Tonelli M, Sacks F, Arnold M, Moye L, Davis B et al. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation 2008; 117 (2): 163–168. doi.org/10.1161/ CIRCULATIONAHA.107.727545.
40. Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB et al. Acute phase response and evolution of familial Mediterranean fever. Lancet (London, England) 1999; 353 (9162): 1415. doi: 10.1016/S0140-6736(99)00990-3.
41. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011; 7 (2): 105–112. doi.org/10.1038/nrrheum.2010.181.
42. Onen F. Familial Mediterranean fever. Rheumatol Int 2006; 26 (6): 489–496. doi.org/10.1007/s00296-005-0074-3.
43. Sari A, Bodakci E, Armagan B, Satis H, Atas N et al. Phenotypic characterisation of Familial Mediterranean Fever patients harboring variants of uncertain significance. Turk J Med Sci 2021; 51 (4): 1695-1701. doi: 10.3906/sag-2011-273.
44. Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis- -phenotype-genotype correlation, treatment and prognosis. J Nephrol 2003; 16 (3): 431–434.